GlassScriptPhysician profile
Amrika Maharaj
NPI 1851891428
$16,047.38
in general payments reported to CMS, 2019-2025
35 companies · $2,726 in 2025
The $2,726 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,034 · 2022: $5,172 · 2023: $3,182 · 2024: $934 · 2025: $2,726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,722 · Travel and Lodging: $3,120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,721.52 |
| Travel and Lodging | $3,119.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $9,227.34 | 2021-2025 | Mazor X System, Stealthstation S8 Platform, O-Arm |
| Abbott Laboratories | $2,783.01 | 2021-2023 | Proclaim |
| Baxter Healthcare | $720.07 | 2021-2025 | Floseal, Tisseel, Perclot |
| Abbvie INC. | $380.22 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $302.57 | 2021-2024 | Ultomiris, Soliris |
| Ucb, INC. | $289.04 | 2023-2025 | Briviact, Zilbrysq, Rystiggo |
| Orthofix Medical, INC. | $256.53 | 2021-2024 | Spinal-Stim, Cervical-Stim, Spinal-Stim |
| Pacira Pharmaceuticals Incorporated | $245.10 | 2022-2025 | Exparel |
| Takeda Pharmaceuticals U.S.A., INC. | $220.33 | 2022-2025 | Hyqvia, Gammagard |
| Integra Lifesciences Corporation | $196.55 | 2024-2025 | Codman Certas, Cusa Clarity, Codman Hakim |
| Emd Serono, INC. | $147.53 | 2021-2024 | Mavenclad |
| Irras USA, INC. | $133.33 | 2022 | |
| Neurelis, INC. | $109.95 | 2021-2025 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $89.97 | 2021-2025 | Austedo Xr, Austedo Xr |
| Csl Behring | $81.12 | 2021-2025 | Hizentra |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $79.17 | 2023-2024 | Vyepti |
| Sk Life Science, INC. | $76.92 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $70.21 | 2021 | |
| Acadia Pharmaceuticals INC | $69.25 | 2022-2025 | Nuplazid |
| Alnylam Pharmaceuticals INC. | $64.96 | 2023-2025 | Onpattro |
| Caris Mpi, INC. | $57.27 | 2025 | Mi Cancer Seek |
| Almatica Pharma LLC | $55.24 | 2021 | |
| Lilly USA, LLC | $50.05 | 2023-2024 | Amyvid |
| Greenwich Biosciences, INC. | $41.41 | 2021 | |
| Genzyme Corporation | $39.22 | 2021-2025 | |
| Merz Pharmaceuticals, LLC | $38.67 | 2024-2025 | Xeomin, Inbrija, Ampyra |
| Corium, LLC | $38.48 | 2023 | Adlarity |
| Biogen, INC. | $35.12 | 2024-2025 | Skyclarys |
| Ani Pharmaceuticals, INC. | $34.61 | 2025 | Purified Cortrophin Gel |
| Eisai INC. | $25.00 | 2023 | |
| Tg Therapeutics, INC. | $21.89 | 2024 | |
| Janssen Pharmaceuticals, INC | $20.02 | 2024 | Xarelto |
| Nalu Medical, INC. | $17.67 | 2022 | |
| Jazz Pharmaceuticals INC. | $17.04 | 2022 | |
| Grifols USA, LLC | $12.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amrika Maharaj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.